Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-3102

- PMLiVE

Keytruda ups survival in lung cancer, misses secondary target

Data shows Keytruda fails to beat BMS' Opdivo

Merck & Co reorganises its HCP communities, hands Univadis to Physicians Interactive

Physicians Interactive outlines globalambitions for its newly-expanded network

- PMLiVE

Novo Nordisk finally bags insulin degludec approval in US

Aims to get Tresiba and Ryzodeg back on course 

- PMLiVE

FDA rejects AZ’s diabetes combination

Wants to see more trial data on saxagliptin / dapagliflozin

Eli Lilly HQ

Lilly acquires rights to intranasal glucagon spray

Could be first needle-less emergency treatment for hypoglycaemia

Bristol-Myers Squibb (BMS) building

BMS gets OK for broader Opdivo use in lung cancer

US regulator'sdecision allows firm to edge in front of Merck & Co's Keytruda

- PMLiVE

Indian court blocks generic of Merck’s Januvia

Follows a series of setbacks in Indian courts for multinational pharma companies

- PMLiVE

Merck gets lung cancer OK for Keytruda in US

Highlights increased understanding of molecular processes in cancer

MSD launches preventative healthcare accelerator

Joins forces with Wayra Open Future for VelocityHealth fund

- PMLiVE

Merck gets first OK for once-weekly DPP-4 inhibitor

Marizev approved in Japan

- PMLiVE

Jardiance survival data wows diabetes conference

BoehringerIngelheim and Eli Lilly release top-line findings from landmark trial at EASD

- PMLiVE

New data arms Novo Nordisk for insulin battle with Sanofi

Tresibaand Xultophy boosted by studies presented at EASD 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links